BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales

Reuters

Feb 12, 2025

BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales

** California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs

** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday

A HEALTHY PROGNOSIS

** J.P.Morgan ("overweight," PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis $(PBC)$ in 2025, leading to optimism about co's future

** Mizuho ("outperform," PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes

** Piper Sandler ("overweight," PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones

** RBC Capital Markets ("sector perform," PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug

(Reporting by Rashika Singh in Bengaluru)

((rashika.singh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510532561"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510532561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510532561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 17:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510532561","market":"us","top_or_hot":-1,"title":"BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales</title></head><body><p>** California-based drugmaker Gilead Sciences <span>GILD.O</span> posted <span>Q4</span> results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs</p><p>** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday</p><p>     A HEALTHY PROGNOSIS </p><p>** J.P.Morgan (\"overweight,\" PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis <a href=\"https://laohu8.com/S/PBC\">$(PBC)$</a> in 2025, leading to optimism about co's future</p><p>** Mizuho (\"outperform,\" PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes</p><p>** Piper Sandler (\"overweight,\" PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones</p><p>\n        ** RBC Capital Markets (\"sector perform,\" PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug</p><p> (Reporting by Rashika Singh in Bengaluru)</p><p> ((rashika.singh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-12 17:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales</title></head><body><p>** California-based drugmaker Gilead Sciences <span>GILD.O</span> posted <span>Q4</span> results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs</p><p>** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday</p><p>     A HEALTHY PROGNOSIS </p><p>** J.P.Morgan (\"overweight,\" PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis <a href=\"https://laohu8.com/S/PBC\">$(PBC)$</a> in 2025, leading to optimism about co's future</p><p>** Mizuho (\"outperform,\" PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes</p><p>** Piper Sandler (\"overweight,\" PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones</p><p>\n        ** RBC Capital Markets (\"sector perform,\" PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug</p><p> (Reporting by Rashika Singh in Bengaluru)</p><p> ((rashika.singh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nL4N3P30N5:1","article_id":"2510532561","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510532561","pubTimestamp":1739353065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales** California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday     A HEALTHY PROGNOSIS ** J.P.Morgan  sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis  in 2025, leading to optimism about co's future** Mizuho  sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes** Piper Sandler  sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones. ** RBC Capital Markets  says they are cautious about complexities and costs associated with CAR-T for ca","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"BUZZ-Street View：分析师对吉利德的前景持乐观态度，艾滋病毒药物销售强劲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales** California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday     A HEALTHY PROGNOSIS ** J.P.Morgan (\"overweight,\" PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis $(PBC)$ in 2025, leading to optimism about co's future** Mizuho (\"outperform,\" PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes** Piper Sandler (\"overweight,\" PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones\n        ** RBC Capital Markets (\"sector perform,\" PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug (Reporting by Rashika Singh in Bengaluru) ((rashika.singh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}